Mitogen-activated protein kinase 8-interacting protein 3 (MAPK8IP3) (MAPK8IP3)

Mitogen-activated protein kinase 8-interacting protein 3 (MAPK8IP3), also known as JIP3, is a large scaffold protein that plays a pivotal role in the organization of the c-Jun N-terminal kinase (JNK) signaling pathway and the regulation of axonal transport (UniProt Q9UPT6). It acts as an adapter, linking JNK signaling components to molecular motors like kinesin-1 and dynein, which is essential for the movement of vesicles and organelles along axons in the central nervous system (NCBI Gene 23162). Proper functioning of the MAPK8IP3 RNA transcript and its subsequent protein product is vital for neuronal development, axonal guidance, and synaptic maintenance (Platzer et al., 2019). Mutations in this gene are associated with a neurodevelopmental disorder characterized by intellectual disability, motor delays, and structural brain abnormalities such as thin corpus callosum or periventricular nodular heterotopia (OMIM 605432). Currently, there are no approved pharmacological agents that directly target MAPK8IP3; however, the RNA transcript is a potential target for precision medicine approaches, including antisense oligonucleotides (ASOs) or gene therapy, to address loss-of-function or dominant-negative effects (Iwasawa et al., 2021). Therapeutic development faces challenges due to the protein's complex role in multiple signaling pathways and its necessity for normal brain architecture.

Other names

JIP3JNK-interacting protein 3JNK-signaling adapter protein 1JSAP1Syd-2

Modulation of protein expression via RNA-targeted therapies (e.g., antisense oligonucleotides) to restore functional levels or reduce toxic variants.